Apnimed, Inc.

APMD Nasdaq SEC CIK 1745648
Follow Apnimed Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.5M −71.8% vs same quarter last year
Net income −$29.5M −170.6% vs same quarter last year
EPS, diluted −$1.05 +54.1% vs same quarter last year
Operating cash flow −$21.2M −22.6% vs same quarter last year
Revenue by quarter
$17.1M
$8.8M
$12.1M
$2.5M
Q2 25 Q3 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing